Hot Features
Premium
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Protara Therapeutics Inc | TARA | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 2.98 | 03:47:10 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 2.98 |
| Trades | Shares Traded | Average Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 1.04 - 5.10 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| - | 0 | US$ 2.98 | USD |
Protara Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 9.6M | 11.43M | - | 0 | -40.42M | -3.54 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Protara Therapeutics News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical TARA Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 3.01 | 3.23 | 2.7621 | 3.00 | 398,388 | -0.03 | -1.00% |
| 1 Month | 4.03 | 5.10 | 2.61 | 3.39 | 616,860 | -1.05 | -26.05% |
| 3 Months | 2.74 | 5.10 | 2.61 | 3.51 | 271,702 | 0.24 | 8.76% |
| 6 Months | 1.26 | 5.10 | 1.04 | 3.18 | 158,184 | 1.72 | 136.51% |
| 1 Year | 3.18 | 5.10 | 1.04 | 3.06 | 92,866 | -0.20 | -6.29% |
| 3 Years | 11.08 | 11.3572 | 1.04 | 5.45 | 88,761 | -8.10 | -73.10% |
| 5 Years | 25.20 | 67.079 | 1.04 | 9.20 | 82,242 | -22.22 | -88.17% |
Protara Therapeutics Description
| Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with rare and specialty diseases. The Protara team prioritizes creativity, diverse perspectives and tenacity to expedite our goal of bringing life-changing therapies to people with limited treatment options. The company discovers, develops, and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD). |
